A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Market
0.0%
Details
- Resolved Date
- 11/20/23
- Study Completion
- 3/1/29
- Company
- Agios Pharmaceuticals, Inc.
- Ticker
- AGIO
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 87
- Volume
- $0
- NCT
- NCT05490446
- Drug Description
- This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Agios publicly reported a trial-specific Phase 2a readout for NCT05490446 and explicitly framed it as positive: “clinical proof-of-concept,” with “favorable efficacy” and a “positive benefit-risk profile,” then advanced the program into Phase 2b. That is a clear positive public readout for this Phase 2 study.
Sources
Sponsorinvestor.agios.com11/20/23
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
Agios said clinical proof-of-concept was achieved in Phase 2a; based on favorable efficacy and a positive benefit-risk profile, it planned to advance AG-946 into Phase 2b.
View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05490446 | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
ClinicalTrials.gov identifies NCT05490446 as the Phase 2a/2b AG-946/tebapivat study in lower-risk MDS, matching the trial named in the Agios Phase 2a readout.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
